These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 20395065

  • 1. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
    Gahramanov S, Raslan AM, Muldoon LL, Hamilton BE, Rooney WD, Varallyay CG, Njus JM, Haluska M, Neuwelt EA.
    Int J Radiat Oncol Biol Phys; 2011 Feb 01; 79(2):514-23. PubMed ID: 20395065
    [Abstract] [Full Text] [Related]

  • 2. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.
    Gahramanov S, Muldoon LL, Varallyay CG, Li X, Kraemer DF, Fu R, Hamilton BE, Rooney WD, Neuwelt EA.
    Radiology; 2013 Mar 01; 266(3):842-52. PubMed ID: 23204544
    [Abstract] [Full Text] [Related]

  • 3. Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol.
    Dósa E, Guillaume DJ, Haluska M, Lacy CA, Hamilton BE, Njus JM, Rooney WD, Kraemer DF, Muldoon LL, Neuwelt EA.
    Neuro Oncol; 2011 Feb 01; 13(2):251-60. PubMed ID: 21163809
    [Abstract] [Full Text] [Related]

  • 4. Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors.
    Thompson EM, Guillaume DJ, Dósa E, Li X, Nazemi KJ, Gahramanov S, Hamilton BE, Neuwelt EA.
    J Neurooncol; 2012 Aug 01; 109(1):105-14. PubMed ID: 22528798
    [Abstract] [Full Text] [Related]

  • 5. Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care.
    Varallyay CG, Nesbit E, Horvath A, Varallyay P, Fu R, Gahramanov S, Muldoon LL, Li X, Rooney WD, Neuwelt EA.
    J Magn Reson Imaging; 2018 Aug 01; 48(2):441-448. PubMed ID: 29314418
    [Abstract] [Full Text] [Related]

  • 6. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging.
    Hamilton BE, Nesbit GM, Dosa E, Gahramanov S, Rooney B, Nesbit EG, Raines J, Neuwelt EA.
    AJR Am J Roentgenol; 2011 Oct 01; 197(4):981-8. PubMed ID: 21940589
    [Abstract] [Full Text] [Related]

  • 7. Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol.
    Gahramanov S, Muldoon LL, Li X, Neuwelt EA.
    Radiology; 2011 Dec 01; 261(3):796-804. PubMed ID: 21940504
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
    Nasseri M, Gahramanov S, Netto JP, Fu R, Muldoon LL, Varallyay C, Hamilton BE, Neuwelt EA.
    Neuro Oncol; 2014 Aug 01; 16(8):1146-54. PubMed ID: 24523362
    [Abstract] [Full Text] [Related]

  • 9. Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.
    Barajas RF, Hamilton BE, Schwartz D, McConnell HL, Pettersson DR, Horvath A, Szidonya L, Varallyay CG, Firkins J, Jaboin JJ, Kubicky CD, Raslan AM, Dogan A, Cetas JS, Ciporen J, Han SJ, Ambady P, Muldoon LL, Woltjer R, Rooney WD, Neuwelt EA.
    Neuro Oncol; 2019 Mar 18; 21(4):517-526. PubMed ID: 30277536
    [Abstract] [Full Text] [Related]

  • 10. High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle.
    Varallyay CG, Nesbit E, Fu R, Gahramanov S, Moloney B, Earl E, Muldoon LL, Li X, Rooney WD, Neuwelt EA.
    J Cereb Blood Flow Metab; 2013 May 18; 33(5):780-6. PubMed ID: 23486297
    [Abstract] [Full Text] [Related]

  • 11. Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.
    Netto JP, Schwartz D, Varallyay C, Fu R, Hamilton B, Neuwelt EA.
    Fluids Barriers CNS; 2016 Dec 20; 13(1):23. PubMed ID: 27998280
    [Abstract] [Full Text] [Related]

  • 12. Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas.
    Horváth A, Varallyay CG, Schwartz D, Toth GB, Netto JP, Barajas R, Várallyay P, Szidonya L, Firkins J, Youngers E, Fu R, Ambady P, Bogner P, Neuwelt EA.
    Magn Reson Med; 2018 Jul 20; 80(1):224-230. PubMed ID: 29205477
    [Abstract] [Full Text] [Related]

  • 13. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.
    Provenzale JM, York G, Moya MG, Parks L, Choma M, Kealey S, Cole P, Serajuddin H.
    AJR Am J Roentgenol; 2006 Oct 20; 187(4):1036-42. PubMed ID: 16985154
    [Abstract] [Full Text] [Related]

  • 14. Visual inspection of MR relative cerebral blood volume maps has limited value for distinguishing progression from pseudoprogression in glioblastoma multiforme patients.
    Kerkhof M, Tans PL, Hagenbeek RE, Lycklama À Nijeholt GJ, Holla FK, Postma TJ, Straathof CS, Dirven L, Taphoorn MJ, Vos MJ.
    CNS Oncol; 2017 Oct 20; 6(4):297-306. PubMed ID: 28984142
    [Abstract] [Full Text] [Related]

  • 15. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
    Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL.
    Neuro Oncol; 2015 Aug 20; 17(8):1148-56. PubMed ID: 25646027
    [Abstract] [Full Text] [Related]

  • 16. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
    Boxerman JL, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, Pope WB, Safran H.
    Am J Clin Oncol; 2017 Jun 20; 40(3):228-234. PubMed ID: 25436828
    [Abstract] [Full Text] [Related]

  • 17. Differentiation of Glioblastoma and Solitary Brain Metastasis by Gradient of Relative Cerebral Blood Volume in the Peritumoral Brain Zone Derived from Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging.
    She D, Xing Z, Cao D.
    J Comput Assist Tomogr; 2019 Jun 20; 43(1):13-17. PubMed ID: 30015801
    [Abstract] [Full Text] [Related]

  • 18. Longitudinal, leakage corrected and uncorrected rCBV during the first-line treatment of glioblastoma: a prospective study.
    Steidl E, Müller M, Müller A, Herrlinger U, Hattingen E.
    J Neurooncol; 2019 Sep 20; 144(2):409-417. PubMed ID: 31321614
    [Abstract] [Full Text] [Related]

  • 19. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.
    Leu K, Boxerman JL, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM.
    J Magn Reson Imaging; 2016 Nov 20; 44(5):1229-1237. PubMed ID: 26971534
    [Abstract] [Full Text] [Related]

  • 20. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
    Park JE, Kim HS, Kim N, Borra R, Mouridsen K, Hansen MB, Kim YH, Hong CK, Kim JH.
    Eur Radiol; 2024 May 20; 34(5):3061-3073. PubMed ID: 37848773
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.